98 related articles for article (PubMed ID: 21358259)
1. Out foxing bcr-abl.
Claxton DF
Cancer Biol Ther; 2011 Apr; 11(8):769-70. PubMed ID: 21358259
[No Abstract] [Full Text] [Related]
2. Bortezomib treatment causes remission in a Ph+ALL patient and reveals FoxO as a theranostic marker.
Dewar R; Chen ST; Yeckes-Rodin H; Miller K; Khosravi-Far R
Cancer Biol Ther; 2011 Mar; 11(6):552-8. PubMed ID: 21282974
[TBL] [Abstract][Full Text] [Related]
3. Recent advancements of bortezomib in acute lymphocytic leukemia treatment.
Du XL; Chen Q
Acta Haematol; 2013; 129(4):207-14. PubMed ID: 23295437
[TBL] [Abstract][Full Text] [Related]
4. [Clinical analysis of bortezomib combined with chemotherapy for one case of refractory acute lymphocytic leukemia].
Xu JJ; Hu XH; Shen YY
Zhonghua Xue Ye Xue Za Zhi; 2011 Oct; 32(10):697-8. PubMed ID: 22339831
[No Abstract] [Full Text] [Related]
5. Sorafenib induces apoptosis specifically in cells expressing BCR/ABL by inhibiting its kinase activity to activate the intrinsic mitochondrial pathway.
Kurosu T; Ohki M; Wu N; Kagechika H; Miura O
Cancer Res; 2009 May; 69(9):3927-36. PubMed ID: 19366808
[TBL] [Abstract][Full Text] [Related]
6. [The anti-leukemic effects of imatinib, daunorubicin and bortezomib on two leukemia cell lines with Ph(+)].
Yang X; Yang L; Gong YP; Chang H; Zhou RQ; Xing HY; Zheng BH
Sichuan Da Xue Xue Bao Yi Xue Ban; 2010 Sep; 41(5):793-6. PubMed ID: 21302443
[TBL] [Abstract][Full Text] [Related]
7. Toxic non-resorptive internal hydrocephalus as a result of haemorrhagic ventriculitis during induction chemotherapy of Bcr-Abl positive acute lymphoblastic leukaemia.
Ramadanova K; Hoff H; Gökbuget N; Reuner U; Hamann S; Ehninger G; Schaich M
Ann Hematol; 2010 Feb; 89(2):221-3. PubMed ID: 19575198
[No Abstract] [Full Text] [Related]
8. Combination therapy with TRAIL: Recent developments and potential pitfalls.
Voelkel-Johnson C
Cancer Biol Ther; 2009 Jan; 8(1):81-3. PubMed ID: 19127121
[No Abstract] [Full Text] [Related]
9. Morphoproteomics and bortezomib/dexamethasone-induced response in relapsed acute lymphoblastic leukemia.
Brown RE; Bostrom B; Zhang PL
Ann Clin Lab Sci; 2004; 34(2):203-5. PubMed ID: 15228234
[TBL] [Abstract][Full Text] [Related]
10. Bortezomib and sphingosine kinase inhibitor interact synergistically to induces apoptosis in BCR/ABl+ cells sensitive and resistant to STI571 through down-regulation Mcl-1.
Li QF; Yan J; Zhang K; Yang YF; Xiao FJ; Wu CT; Wang H; Wang LS
Biochem Biophys Res Commun; 2011 Feb; 405(1):31-6. PubMed ID: 21195056
[TBL] [Abstract][Full Text] [Related]
11. Successful T-cell acute lymphoblastic leukemia treatment with proteasome inhibitor bortezomib based on evaluation of nuclear factor-κB activity.
Hu X; Xu J; Sun A; Shen Y; He G; Guo F
Leuk Lymphoma; 2011 Dec; 52(12):2393-5. PubMed ID: 21745166
[No Abstract] [Full Text] [Related]
12. Adaphostin and bortezomib induce oxidative injury and apoptosis in imatinib mesylate-resistant hematopoietic cells expressing mutant forms of Bcr/Abl.
Dasmahapatra G; Nguyen TK; Dent P; Grant S
Leuk Res; 2006 Oct; 30(10):1263-72. PubMed ID: 16481037
[TBL] [Abstract][Full Text] [Related]
13. Bortezomib and TRAIL: a perfect match for apoptotic elimination of tumour cells?
de Wilt LH; Kroon J; Jansen G; de Jong S; Peters GJ; Kruyt FA
Crit Rev Oncol Hematol; 2013 Mar; 85(3):363-72. PubMed ID: 22944363
[TBL] [Abstract][Full Text] [Related]
14. Overexpression of the PSMB5 gene contributes to bortezomib resistance in T-lymphoblastic lymphoma/leukemia cells derived from Jurkat line.
Lü S; Chen Z; Yang J; Chen L; Gong S; Zhou H; Guo L; Wang J
Exp Hematol; 2008 Oct; 36(10):1278-84. PubMed ID: 18562081
[TBL] [Abstract][Full Text] [Related]
15. BCR-ABL-mediated upregulation of PRAME is responsible for knocking down TRAIL in CML patients.
De Carvalho DD; Binato R; Pereira WO; Leroy JM; Colassanti MD; Proto-Siqueira R; Bueno-Da-Silva AE; Zago MA; Zanichelli MA; Abdelhay E; Castro FA; Jacysyn JF; Amarante-Mendes GP
Oncogene; 2011 Jan; 30(2):223-33. PubMed ID: 20838376
[TBL] [Abstract][Full Text] [Related]
16. Initial testing (stage 1) of the proteasome inhibitor bortezomib by the pediatric preclinical testing program.
Houghton PJ; Morton CL; Kolb EA; Lock R; Carol H; Reynolds CP; Keshelava N; Maris JM; Keir ST; Wu J; Smith MA
Pediatr Blood Cancer; 2008 Jan; 50(1):37-45. PubMed ID: 17420992
[TBL] [Abstract][Full Text] [Related]
17. The proteasome inhibitor PS-341 inhibits growth and induces apoptosis in Bcr/Abl-positive cell lines sensitive and resistant to imatinib mesylate.
Gatto S; Scappini B; Pham L; Onida F; Milella M; Ball G; Ricci C; Divoky V; Verstovsek S; Kantarjian HM; Keating MJ; Cortes-Franco JE; Beran M
Haematologica; 2003 Aug; 88(8):853-63. PubMed ID: 12935973
[TBL] [Abstract][Full Text] [Related]
18. Arsenic trioxide and bortezomib interact synergistically to induce apoptosis in chronic myelogenous leukemia cells resistant to imatinib mesylate through Bcr/Abl‑dependent mechanisms.
Xu W; Wei W; Yu Q; Wu C; Ye C; Wu Y; Yan H
Mol Med Rep; 2014 Sep; 10(3):1519-24. PubMed ID: 24939418
[TBL] [Abstract][Full Text] [Related]
19. Drug interactions between the proteasome inhibitor bortezomib and cytotoxic chemotherapy, tumor necrosis factor (TNF) alpha, and TNF-related apoptosis-inducing ligand in prostate cancer.
An J; Sun YP; Adams J; Fisher M; Belldegrun A; Rettig MB
Clin Cancer Res; 2003 Oct; 9(12):4537-45. PubMed ID: 14555528
[TBL] [Abstract][Full Text] [Related]
20. Serial minimal residual disease (MRD) analysis as a predictor of response duration in Philadelphia-positive acute lymphoblastic leukemia (Ph+ALL) during imatinib treatment.
Scheuring UJ; Pfeifer H; Wassmann B; Brück P; Gehrke B; Petershofen EK; Gschaidmeier H; Hoelzer D; Ottmann OG
Leukemia; 2003 Sep; 17(9):1700-6. PubMed ID: 12970767
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]